Bolded words are present in the MOGlossary

1. Overview & Epidemiology

Overview

Myelin oligodendrocyte glycoprotein antibody-associated disease (**MOGAD**) is a rare inflammatory disease of the **central nervous system** (**CNS**). In **MOGAD**, the immune system attacks the protective coating around nerve fibers, called **myelin**, leading to damage in areas like the **optic nerves**, brain, and/or spinal cord[1].

How does MOGAD Develop?

While the exact cause of **MOGAD** is unknown, it is thought to be caused by autoantibodies known as **myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG),** which are **antibodies** in the immune system that mistakenly target healthy proteins in the body[2]. In **MOGAD**, these autoantibodies cause damage to healthy **MOG** proteins on the outer protective surface of nerve cells, leading to **demyelination**[1,3]. Demyelination can be compared to a power cord on a lamp short-circuiting when its protective plastic coating is stripped away. Without this insulation, the flow of electricity is disrupted, causing the lamp to flicker or fail to work. Similarly, in MOGAD, the loss of myelin impairs nerve signal transmission, leading to disruptions in nerve function[4].

Recently, doctors have recognized that **MOGAD** is a distinct disease, separate from other neurological conditions like **Neuromyelitis Optica Spectrum Disorder (NMOSD), Chronic Relapsing Inflammatory Optic Neuropathy (CRION)** and **Multiple Sclerosis (MS).** Although these conditions can have similar symptoms, improved testing for **MOG antibodies** has made it easier to accurately diagnose **MOGAD** and tell it apart from other **demyelinating** diseases of the **CNS**[5-6].

Who is Affected by MOGAD?

Prevalence and incidence of **MOGAD** is still being studied, and the exact numbers can vary by region. However, research from different parts of the world shows that **MOGAD** is relatively rare. Estimates suggest that about 1.3 to 2.5 people per 100,000 have **MOGAD,** and each year, there are around 3.4-4.8 new cases per million people[7].

Although **MOGAD** affects both men and women, and can happen at any age, it most commonly presents in those 28-30 years of age[7]. Around 30% of **MOGAD** cases occur in children, making it one of the more common causes of acquired **central nervous system** (**CNS) demyelinating** syndromes in young people[8]. Currently, unlike **MS** and **NMOSD, MOGAD** shows no clear racial preponderance or strong human leucocyte antigen associations, though further research is needed on how ethnicity may influence **MOGAD** expression[8,9]. As doctors become more familiar with **MOGAD** and testing becomes more widely available, it's likely that more cases will be diagnosed in the future[7].

2. Signs & Symptoms

MOGAD typically presents as a sudden onset of symptoms, referred to as an **acute** attack, which can vary in type and severity. It can also vary in how it presents over one's lifetime, where it can be **multiphasic** (relapsing) or **monophasic**[10,11,12]**.**

- **Multiphasic**: characterized by recurrent attacks following the initial episode
- **Monophasic:** an individual experiences only a single attack throughout their lifetime[13].

Monophasic classification represents approximately 50% of **MOGAD** cases. Emerging research suggests that young adults (below the age of 40) have a higher risk of **relapse** compared to those above the age of 40[8,14]. However, the classification of **MOGAD** as **monophasic** has recently been challenged, and further research is needed. It is suggested that MOGAD may predominantly be a relapsing disease when observed over a longer follow-up period, with the monophasic nature of some individuals possibly being an artifact of insufficient observation time[8].

Individuals with **MOGAD** may have varying levels of **MOG-IgG** over time, and higher titers are associated with a higher likelihood of an accurate diagnosis, as these elevated levels are more detectable in tests[15,16]. Increased **MOG-IgG** titers enhance diagnostic sensitivity, helping differentiate **MOGAD** from other demyelinating conditions[15,16]. Additionally, fluctuations in **MOG-IgG** levels can reflect disease progression and treatment response, providing valuable insights into disease activity and guiding therapeutic decisions[15,16,17].

In children, **ADEM** is the most common clinical presentation, while **ON** and **myelitis** are more commonly observed in adults[11]. In addition to these symptoms, fatigue is a significant and debilitating aspect of **MOGAD**[31]. Factors such as older age**, bilateral optic neuritis (ON)**, other existing health conditions (**comorbidities**), and ongoing disease activity can worsen the severity of fatigue[31]. Furthermore, individuals living with **MOGAD** often show decreased **visuomotor processing speed** (such as difficulty reading or writing) and **semantic fluency** (such as difficulty with word retrieval), both of which correlate with the presence of cerebral **lesions**[32]. **Uhthoff's phenomenon** is a temporary (less than 24 hours), worsening of neurological symptoms related to a demyelinating disorder such as MOGAD. This may occur when the bodies core temperature increases due to prolonged exposure to excessive heat (e.g., from hot weather, exercise, fever, saunas, or hot tubs)[33].

3. Diagnosis

Diagnosing **MOGAD** based on symptoms alone can be challenging due to the similarities with **NMOSD, CRION** and **MS**[10]. To establish a diagnosis, these other conditions must be excluded. Many individuals living with MOGAD may have previously been misdiagnosed with atypical MS or seronegative NMOSD or CRION, however are now considered to have MOGAD with a distinct clinical presentation[8]. This requires a careful differential diagnosis using clinical symptoms, laboratory results, and imaging findings. Prompt testing, especially in the **acute** phase of the disease, is critical for an accurate diagnosis and timely treatment, which can help improve outcomes for individuals living with **MOGAD**[34]. For

more information on the diagnostic criteria please visit the following page: https://mogproject.org/demystifying-the-diagnosis-of-mogad-take-home-points-for-patients-from-the-2023-international-mogad-panel-proposed-diagnostic-criteria/

MOG-IgG Testing:

The most important criterion for **MOGAD** diagnosis is the presence of **MOG-IgG antibodies**. These **antibodies** can be detected in blood or **cerebrospinal fluid (CSF),** and their presence is a key marker for **MOGAD**. Below are key points related to the testing process for these **antibodies:**

- Serum testing is the most common method
- The live cell-based **assay** is the gold standard for testing **MOG-IgG** levels yet must be done prior to any treatment[5].
- **MOG-IgG** levels may decrease over time following an **acute** attack, which can result in false negative results.
    - For this reason, testing should be performed promptly after the onset of symptoms and repeated if necessary[35].
- **CSF** analysis may be useful when blood tests yield inconclusive results
    - **MOG-IgG** has been found in **CSF** of 12% of individuals who are **seronegative** yet present with symptoms of **MOGAD,** however this presence may be indicative of a more severe clinical presentation[36,37,38].

However, the presence of **MOG-IgG antibodies** alone is not sufficient for a diagnosis, as **antibody** levels can fluctuate over time, and low levels may result in false-positives or negatives[15].

Imaging:

- **Magnetic Resonance Imaging (MRI)** is crucial in assessing **inflammation** and/or **lesions** in the **optic nerves**, spinal cord, and brain, which are commonly seen in **MOGAD**[5].
    - However, in about 10% of cases, **MRI** findings may initially appear normal at the onset of symptoms, even when individuals living with **MOGAD** experience significant clinical disability and repeat MRI after days/weeks may be necessary[39].
- **Optical coherence tomography (OCT)** is often performed for evaluating **optic nerve** damage, which allows for direct visualization of the nerve's condition.
- **Visual field testing** can also be used to detect blind spots or other visual impairments caused by **optic neuritis**[5,40].

4. Treatments- **Acute** and **Preventative** Care

Although there are currently no FDA-approved treatments specifically for **MOGAD**, various therapies can help manage symptoms, reduce **relapses** and control inflammation[5]. Treatment strategies vary depending on whether the individual is in the **acute** phase or needs long-term **preventive** care.

Acute Treatment

During the **acute** phase, the primary goal is to reduce **inflammation** and prevent further damage by targeting and lowering the levels of **MOG-IgG antibodies**. High-dose corticosteroids are typically the first-line treatment, administered either orally or **intravenously**. These **steroids** work by suppressing the immune system and reducing **inflammation.** However, prolonged use of corticosteroids can lead to **steroid** dependency and other side effects such as weight gain, elevated blood pressure, elevated blood sugar, cataracts, insomnia, osteoporosis, edema, heart rhythm abnormalities, muscle atrophy and more[5,40]. As such, after the initial **acute** attack, **steroid** tapering may be performed to gradually reduce the dosage of corticosteroids to minimize side effects while continuing to suppress **inflammation**. **Steroid** tapering must be done carefully to avoid a rebound increase in **inflammation**.

In some cases, additional treatments may be used in combination with or in place of **steroids**. This may include:

- **Plasma exchange (PLEX/ plasmapheresis)** can be performed to remove harmful **MOG-IgG antibodies** from the blood, offering additional immune modulation[5,41]. For risks/ side effects of PLEX, please see the following resources:
  - https://my.clevelandclinic.org/health/treatments/24197-plasmapheresis-plasma-exchange#risks-benefits
  - https://www.medicalnewstoday.com/articles/321451#risks-and-side-effects
- **Corticosteroids** help reduce **inflammation** and supress the immune response from the **acute** attack[5,40]. For the risks/ side effects of corticosteroids, please see the following resources:
  - https://my.clevelandclinic.org/health/treatments/corticosteroids-glucocorticoids#risks-benefits
  - https://www.mayoclinic.org/steroids/art-20045692
- **Intravenous immunoglobulin (IVIG)** involves infusing **antibodies** from healthy donors. The mechanism of action of IVIG is not fully understood but is thought to involve enhanced clearance and interference with MOG **antibodies,** as well as modulation of the immune response[5,42]. For the risks/ side effects of IVIG, please see the following resource:
  - https://www.verywellhealth.com/intravenous-immunoglobulin-ivig-therapy-8643506#toc-side-effects-of-ivig

Preventative Treatment

For individuals living with **MOGAD** who have a history of **relapse**, **preventive** treatments are typically recommended to avoid further relapses and minimize the risk of long-term disability.

After a first MOGAD attack, the decision to initiate long-term, **preventive** therapy depends on how the individual responds to **acute treatment,** the level of damage from the initial attack, and the risk for further relapses. In about 33% of individuals living with **MOGAD**, it is a one-time occurrence, with only one attack in their lifetime[5,8,15]. If the response to **acute treatment** after an initial attack is complete and **MOG-IgG** levels are undetectable, doctors may opt to delay long-term treatment until a second attack occurs. However, if the response to treatment is incomplete, and **MOG-IgG** levels remain elevated, **immunomodulators** may be recommended to prevent further **relapses** and minimize the risk of long-term disability. While there is no defined biomarker indicative of **relapse** in **MOGAD**, some physicians may recommend not to risk a second attack and initiate **preventative** treatment to avoid further damage. Risks of adverse effects from immunosuppressive therapies also need to be taken into consideration. These discussions should be individualized, and shared decision making between the physician and the patient is essential. Treatments to prevent MOGAD relapses may include:

- **Immunomodulators** such as **mycophenolate mofetil, rituximab**[43], **tocilizumab** and **azathioprine**[40,44]. These are used to reduce **inflammation** and prevent future attacks. For more information regarding the efficacy and side effects of immunomodulators, please see the following resources:
    - **Mycophenolate mofetil:**
        - Efficacy: https://www.neurology.org/doi/full/10.1212/NXI.0000000000000705
        - Side effects**:** https://www.webmd.com/drugs/2/drug-4068-2108/mycophenolate-mofetil-oral/mycophenolate-mofetil-oral/details
    - **Rituximab:**
        - Efficacy: https://pmc.ncbi.nlm.nih.gov/articles/PMC9728038/#abstract1
        - Risks/ side effects: https://www.drugs.com/rituximab.html#side-effects
    - **Tocilizumab:**
        - Efficacy: https://pmc.ncbi.nlm.nih.gov/articles/PMC8596357/
        - Side effects: https://www.mayoclinic.org/drugs-supplements/tocilizumab-intravenous-route-subcutaneous-route/description/drg-20073821
    - **Azathioprine:**
        - Efficacy: https://journals.sagepub.com/doi/pdf/10.1177/17562864211054157
        - Side effects: https://my.clevelandclinic.org/health/drugs/9407-azathioprine

- **Intravenous immunoglobulin (IVIG)** or **subcutaneous immunoglobulin (SCIG),** which involves regular **infusions** of **antibodies** from healthy donors[45]. These treatments help neutralize MOG **antibodies** and decrease the immune response that triggers **relapses,** proving highly effective when administered at the correct dosage and interval[5,46,47].
- Low-dose oral corticosteroids may be used for short periods following an attack and are sometimes taken in low doses long-term to prevent **relapses** in adults, though this treatment is not typically prescribed for children given the risks for adverse effects[5,46].

Long-term management of **MOGAD** often involves a combination of these therapies to balance controlling **inflammation** and minimizing the side effects of chronic treatment[5]. Individuals living with **MOGAD** are unresponsive to conventional **MS** therapies like interferon beta and glatiramer, making accurate MOGAD diagnosis crucial for effective treatment[44].

Ongoing **Clinical Trials (**As of February 2025)

Several promising treatments are currently being investigated in **clinical trials**. These treatments include:

- Neonatal Fc receptor inhibitor (FcRn), **rozanolixizumab**. By blocking FcRn, which normally helps preserve **MOG-IgG antibodies** in the body, **rozanolixizumab** accelerates the degradation of MOG-IgG antibodies, thereby reducing the immune response[48,49].
  Rozanolixizumab is currently in Phase 3 of **clinical trials**[1]**.**
  - **Rozanolixizumab** (cosMOG): This randomized, double-blind, placebo-controlled, multicenter study is designed to assess the efficacy and safety of **rozanolixizumab** in adult patients aged 18 to 89 with at least one **relapse** in the past 12 months. The study will include 104 participants worldwide and began on February 2, 2022, with an expected completion date of July 1, 2027.
    For more details: https://mogproject.org/clinical-trials/#cosmog
- **IL-6 receptor** targeted drugs, **satralizumab** and **tocilizumab**, which work to suppress the immune response involved in **MOGAD** attacks. These are in Phase 3 and Phase 2/3 of **clinical trials**, respectively[50,51,52,53].
  - **Satralizumab** (METEOROID): This randomized, double-blind, placebo-controlled, multicenter study aims to evaluate the efficacy, safety, **pharmacokinetics**, and **pharmacodynamics** of **satralizumab** in patients aged 12 years or older with a confirmed diagnosis of **MOGAD.** Eligible participants must have experienced at least one **relapse** in the past 12 months or at least 2 attacks in the past 24 months. The trial, involving 152 participants worldwide, began on August 30, 2022, and is set to conclude on December 31, 2028.
    For more details: https://mogproject.org/clinical-trials/#meteoroid
  - **Tocilizumab** (TOMATO): This randomized, controlled multicenter study aims to evaluate the safety and efficacy of **tocilizumab** in patients aged 12 years or older with a confirmed diagnosis of **MOGAD.** Eligible participants must have experienced at least one

relapse in the past 12 months or at least 2 attacks in the past 24 months. The trial, involving 102 participants in China, began on July 9, 2024, and is set to conclude on July 1, 2026.
For more details: https://clinicaltrials.gov/study/NCT06452537?intr=tocilizumab&cond=MOGAD&rank=1

5. Prognosis and Understanding Relapsing Disease

The prognosis for individuals with MOGAD can vary significantly, making it difficult to predict the likelihood of relapses, their severity, and the extent of recovery following subsequent attacks[11]. While it's suggested that approximately 67% of individuals experience relapses, it is uncertain who will relapse or when these relapses might happen[8]. Understanding **relapse** patterns is crucial for managing the long-term course of the disease and improving patient outcomes.

Risk Factors for **Relapse**

Tracking relapse patterns over time is crucial for assessing the progression of MOGAD, as accumulated disability is believed to result from relapses rather than continuous progression[8]. Certain factors have been associated with an increased risk of **relapse** in individuals living with **MOGAD**:

- Age: Older children[17].
- Gender: Female[54].
- Ethnicity: Hispanic/Latino[54].
- Initial symptoms: Individuals presenting with **ON** as an initial symptom[17].
    - Presence of the non-p42 epitope in patients particularly with an ON phenotype is the first serological marker that may be indicative of relapse[55].
- **Seropositivity**: Persistent **seropositivity** (the presence of **MOG-IgG antibodies**) in blood tests after an **acute** attack may indicate a higher risk of relapse in some individuals[15,17]. However, patients who become seronegative can return to seropositive and experience an attack, and some patients who remain seropositive do not have relapses[56].

Importance of Early Diagnosis and **Relapse** Management

Getting an early diagnosis of **MOGAD** and prompt treatment following the first attack is crucial for preparing individuals living with **MOGAD** for the possibility of future **relapses**[57,58]. **MOGAD** attacks, especially those involving the spinal cord **(myelitis and ADEM),** can cause significant

neurological damage that may be permanent, leading to long-term disability[12]. Individuals living with **MOGAD** who experience **myelitis** during their initial attack are at higher risk of enduring long-term functional impairments[12].

For individuals at high risk of **relapse**, ongoing **preventive** treatment, such as those described above, have been shown to reduce the likelihood of future **relapses**[54]. Interestingly, **ON** is the most common symptom observed during **relapse**, regardless of the symptoms during the initial attack[40].

Early intervention and prompt treatment during **relapses** can help prevent new and permanent damage to the nervous system, which in turn may minimize long-term disability and improve the overall prognosis for individuals living with **MOGAD.** In some instances, this swift treatment allows patients to recover partially or entirely back to their pre-attack baseline[57].

A **pseudo-relapse** in **MOGAD** refers to the temporary recurrence or worsening of neurological symptoms, often triggered by external factors such as heat, stress, infections, or other physical or emotional stressors. Unlike true relapses**, pseudo-relapses** are characterized by their transient nature, with symptoms fluctuating in severity and typically improving within 24-48 hours. Clinically, **pseudo-relapses** can be distinguished from genuine relapses by the absence of new or worsening **lesions** on MRI, indicating that they do not reflect disease progression. However, physicians must exercise caution in making this distinction if there is an exam change, as relapses can occasionally occur despite negative MRI findings[59]. **Pseudo-relapses** are thought to result from factors that exacerbate existing symptoms without triggering active **inflammation** or **demyelination** in **the central nervous system (CNS).**

Impact on Quality of Life

Being diagnosed with **MOGAD** can affect an individual's quality of life (QoL). The physical symptoms of an attack, such as vision impairment, mobility issues and weakness can interfere with daily activities and limit a person's independence. These limitations may affect an individual living with **MOGAD's** ability to:

- Maintain employment
- Manage personal care
- Engage in social or recreational activities

In addition to the physical impact, mental health challenges are common among individuals living with **MOGAD**. Studies have found that these individuals may experience heightened:

- Anxiety[60]
- Depression[60]
- Fatigue[31]
- Cognitive difficulties[60]
- Social isolation[60]

These psychological and emotional burdens often compound the physical challenges of the disease, making effective management of **MOGAD** essential not just for preventing **relapses**, but also for improving overall well-being.

Please see these helpful resources to support living with **MOGAD:**

- Education:
  - Disease Information: https://mogproject.org/resources/
  - Facts Sheets, Patient Brochure, Diagnosis Deep Dive and IVIG/SCIG help: https://mogproject.org/resources/fact-and-information-sheets/
  - Clinical Trial Education: https://mogproject.org/clinical-trials/
  - MOGlossary of terms for MOGAD: https://mogproject.org/resources/moglossary/
  - Educational videos and Q&A webinars: https://mogproject.org/resources/podcasts/
  - MOGmentum infographic learning series: https://mogproject.org/resources/mogmentum/
  - Resources for the Blind and Visually Impaired: https://mogproject.org/resources/for-the-blind/
  - Rocket Surveys: https://mogproject.org/rocket-surveys
- Support:
  - Support Groups: https://mogproject.org/community/support-groups/
  - Connections to Facebook Support Groups: https://mogproject.org/community/connect/
- Community: Stories and Fun Events
  - Community Page: https://mogproject.org/community/
  - MOG Blog: https://mogproject.org/mog-blog-2/
- Collaborative Partner Resources:
  - Siegel Rare Neuroimmune Association: https://wearesrna.org/
  - Guthy Jackson Charitable Foundation: https://guthyjacksonfoundation.org/
  - NMO France Association: https://www.nmo-france.org/

- Child Neurology Foundation: https://www.childneurologyfoundation.org/disorder/myelin-oligodendrocyte-glycoprotein-antibody-disease-mogad/
- National MS Society: https://www.nationalmssociety.org/
- MyMyelitis: https://mymyelitis.com/
- International Autoimmune Encephalitis Society: https://autoimmune-encephalitis.org/

Our YouTube Channel: https://www.youtube.com/@themogproject

6. **Rehabilitative** & Long-Term Care

Rehabilitation therapy can assist in restoring function, improving QoL, and promoting independence for those living with **MOGAD**. Starting **rehabilitation** early following an attack can prevent the complications associated with disuse and addresses functional impairments resulting from neurological damage. **Rehabilitation** strategies are individualized to the specific symptoms and challenges an individual living with **MOGAD** is experiencing after an **acute** attack. These specialists make up the multidisciplinary team focused on ensuring holistic health for individuals living with **MOGAD**[61]**.**

Physical Therapists

Physical therapists play a vital role in addressing mobility issues such as spasticity, muscle weakness, and pain that result from damage to the **central nervous system (CNS)**[62]. This damage can lead to muscle tightness, involuntary contractions, and limited movement[63]. To help manage these challenges, physical therapists develop personalized exercise programs that focus on stretching and strengthening muscles to improve range of motion and restore functional mobility[64,65]. They may also recommend assistive devices, like splints, to support weakened muscles and joints[65]. Pain in **MOGAD** can stem from neuropathic causes, such as nerve damage that results in burning, stabbing, or shooting pain, or from musculoskeletal issues like spasticity and joint pain caused by immobility[63]. Physical therapists help manage pain by improving muscle strength and flexibility through targeted exercises[64,65]. They also use techniques such as massage, stretching, and TENS therapy (Transcutaneous Electrical Nerve Stimulation) to alleviate discomfort and improve overall function[64].

Occupational Therapists

Occupational therapy helps individuals with **MOGAD** regain independence in daily activities while addressing specific symptoms such as pain, balance issues, and fatigue[65,66]. For individuals experiencing musculoskeletal pain or joint stiffness, occupational therapists recommend adaptive tools like reachers or button hooks to reduce strain during tasks such as dressing and eating[65,67]. They also provide ergonomic strategies to

improve comfort and joint mobility[67]. To address balance problems and mobility challenges, occupational therapists evaluate posture and recommend assistive devices like canes or walkers to improve stability[65]. They teach safe mobility techniques to reduce the risk of falls and enhance independence[68]. For those affected by fatigue, occupational therapists guide individuals in energy conservation techniques, helping them prioritize tasks and manage their stamina throughout the day[67,68].

Speech and Language Pathologists

Speech and language pathologists are integral in addressing swallowing difficulties and speech impairments that arise when muscles involved in speech and swallowing are weakened or damaged by **MOGAD**[67]**.** Swallowing therapy is provided to help individuals maintain safe swallowing and reduce the risk of choking, often through techniques like thickened liquids or swallowing exercises[69]. For individuals experiencing speech impairments, speech pathologists offer exercises aimed at improving articulation, breathing, and language skills to enhance clarity and communication[69,70].

Neuropsychologists

Neuropsychologists provide valuable support in managing depression, anxiety, and behavioral issues that can result from neurological changes or the emotional burden of living with **MOGAD**[32,65]. These professionals may help patients cope with mood swings, anxiety, and other emotional challenges, promoting better emotional well-being[32]. Cognitive impairments, such as memory loss and difficulty concentrating, often occur as a result of brain **lesions** caused by **MOGAD**[71,72]. Neuropsychologists assess these cognitive challenges and develop personalized rehabilitation programs, incorporating techniques to improve attention, memory, and problem-solving skills[32]. Additionally, behavioral issues such as impulsivity, irritability, or mood swings occur due to damage in the frontal lobes of the brain[73]. Neuropsychologists use behavioral therapy to address emotional regulation, helping individuals manage and cope with behavioral changes[74,75].

Neuro-ophthalmologists and low vision **rehabilitation** specialists

Neuro-ophthalmologists and low vision **rehabilitation** specialists are vital members of the healthcare team when it comes to addressing low vision caused by optic nerve damage[76,77]. These specialists assess the degree of visual impairment using tools like **Optical Coherence Tomography (OCT)** scans and **visual field tests** to monitor recovery and detect early signs of relapse[77]. In addition to medical treatment, they recommend assistive devices such as magnifiers, screen readers, and modified lighting to assist with daily tasks like reading and using a computer[76]. Low vision **rehabilitation** also involves training individuals in adaptive techniques for safe navigation and performing daily activities despite visual impairments[76].

Urologists

Urologists are directly involved in managing bladder dysfunction, bowel dysfunction, and sexual dysfunction, which are common challenges for individuals living with **MOGAD**[78,79]. Bladder dysfunction can occur when nerve pathways that control the bladder are impaired, resulting in incontinence or urinary retention[78,79]. Urologists help by recommending bladder training, medications such as anticholinergics, and in some cases, catheterization to improve bladder control[80]. Similarly, bowel dysfunction caused by neurological impairment can lead to constipation or fecal incontinence[79]. Urologists recommend dietary modifications, stool softeners, and regular bowel training to manage these symptoms effectively[79]. Sexual dysfunction, often resulting from nerve damage, can affect sexual arousal and function[79,80]. Urologists work with individuals to address this through sexual health counseling, medications, and adaptive devices to improve sexual function and quality of life[79,80].

Chronic Fatigue Specialists

Chronic fatigue specialists are crucial in managing chronic fatigue, a pervasive issue caused by neurological stress and the burden of living with a chronic illness. These specialists teach individuals how to manage their energy effectively through pacing techniques, improving sleep hygiene, and incorporating stress management strategies to help individuals optimize their daily functioning without overexerting themselves[81,82,83]. In some cases, medication may also be used to support individuals in managing symptoms and improving their quality of life[84].

7. Conclusion

While **MOGAD** is a serious and complex medical condition, ongoing research and clinical trials are making excellent progress toward improved treatment outcomes. With appropriate support, individuals living with **MOGAD** can maintain or even improve their quality of life (QoL), maximize functional independence, and manage the condition's complexities. By prioritizing early intervention, personalized treatment plans, and continuous care, individuals with **MOGAD** can lead fulfilling lives despite the challenges posed by the disease.

References:

1. cosMOG – About MOGAD. Available from: https://www.cosmogstudy.com/about-mog-ad/. Accessed on September 30, 2024.
2. Elkon and Casali. Nat Clin Pract Rheumtol. 2009; 4: 491-498. Nature and functions of autoantibodies - PMC
3. Jeyakumar et al. Eye. 2024;38:2289-2301. springernature_eye_3108 2289..2301
4. Harry and Toews. Handbook of Developmental Neurotoxicity. 2007; 87-115. Myelination, Dysmyelination, and Demyelination - PMC
5. Hegen and Reindl. Ther Adv Neurol Disord. 2020;13:1-20. Recent developments in MOG-IgG associated neurological disorders - PubMed

6. Gastaldi et al. J Neurol. 2020;267(23):3555-3564. Cell-based assays for the detection of MOG antibodies: a comparative study - PubMed
7. Hor and Fujihara. Front Neurol. 2023;14:1260358. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide - PubMed
8. Trewin et al. Autoimmun Rev. 2025: 24: 103693 MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally - PubMed
9. Grant-Peters et.al Ann Clin Transl Neurol. 2021: 8: 1502-1507 No strong HLA association with MOG antibody disease in the UK population - PMC
10. Ambrosius et al. Int J Mol Sci. 2020;22:100. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management - PMC
11. Li et al. Front Aging Neurosci. 2022;14:850743. Clinical Features and Imaging Findings of Myelin Oligodendrocyte Glycoprotein-IgG-Associated Disorder (MOGAD) - PubMed
12. Jurynczyk et al. Brain. 2017;140:3128-138. Clinical presentation and prognosis in MOG-antibody disease: a UK study - PubMed
13. Santoro et al., Ann Clin Transl Neurol. 2023: 10: 672-685. Attack phenotypes and disease course in pediatric MOGAD - PMC
14. Satukijchai et al. JAMA Netw Open. 2022; 5: e2142780 Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom - PubMed
15. Lopez-Chiriboga et al. JAMA neurol. 2018;75:1355-1363. Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders - PubMed
16. Wendel et al. Neurol Neuroimmunol Neuroinflamm. 2022: 9: e200035 Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome - PubMed
17. Waters et al. Jama Neurol. 2020;77:82-93. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes - PubMed
18. Asseyer et al. Mult Scler Relat Disord. 2020; 40: 101965. Prodromal headache in MOG-antibody positive optic neuritis - ScienceDirect
19. Rempe et al. Mult Scler Relat Disord. 2021; 48:102718. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience - PubMed
20. Transverse Myelitis. Available from: https://www.ninds.nih.gov/health-information/disorders/transverse-myelitis Accessed on February 2, 2025.
21. Filippi and Rocca. White Matter Diseases. 2020: 12: 109-125. Acute Disseminated Encephalomyelitis - PMC
22. Shilo et al. Eur J Paediatr Neurol. 2016: 20: 361-367. Long-term motor, cognitive and behavioral outcome of acute disseminated encephalomyelitis - ScienceDirect

23. Valencia-Sanchez et al. Ann Neurol. 2022;92:297-302. Cerebral Cortical Encephalitis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease - PubMed
24. Pace et al. Eur J Neurol. 2024: 32: e16550. Cerebral cortical encephalitis in adults with myelin oligodendrocyte glycoprotein antibody-associated disease: A national case series - PMC
25. Jain et al. Mult Scler Relat Disord. 2021: 49: 102759. "FLAMES: A novel burning entity in MOG IgG associated disease" - PubMed
26. Ogawa et al., Neurol Neruoimmunol Neuroinflamm. 2017: 4: e322 MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy - PubMed
27. Maturu et al., 2023. Cureus. 2023;15(2): e34994. Unilateral Autoimmune Encephalitis: A Case Report on a Rare Manifestation of Myelin Oligodendrocyte Glycoprotein Antibody Disease - PMC
28. Banwell et al. Lancet Neurol. 2023: 22:268-282. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria - PubMed
29. Demyelinating Disease. Available from: Demyelinating Disease: What It Is, Symptoms & Treatment Accessed February 2, 2025.
30. Banks et al. J Neurol Neurosurg Psychiatry. 2022: 92: 384-390. Brainstem and Cerebellar Involvement in MOG-IgG Associated Disorder versus Aquaporin-4-IgG and MS - PMC
31. Ladakis et al. Mult Scler J Exp Transl Clin. 2022; 8: 10.1177/20552173221131235. Fatigue is a common symptom in myelin oligodendrocyte glycoprotein antibody disease - Dimitrios C Ladakis, Jennifer Gould, Jenny M Khazen, Julia M Lefelar, Scott Tarpey, Charles J Bies, Rebecca Salky, Kathryn C Fitzgerald, Pavan Bhargava, Bardia Nourbakhsh, Elias S Sotirchos, 2022
32. Passoke et al. J Neurol Neurosurg Psychiatry. 2024; 333994. Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study) - PubMed
33. Panginikkod et al., Uhthoff Phenomenon. 2022 Oct 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing Uhthoff Phenomenon - PubMed
34. Forcadela et al. Neurol Neuroimmunol Neuroinflamm. 2023: 11: e200183. Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria - PubMed
35. Nguyen et al. Mult Scler J Exp Transl Clin. 2024; 10: 2055217241274610. The positive predictive value of MOG-IgG testing based on the 2023 diagnostic criteria for MOGAD - PubMed
36. Carta et al. Neurology. 2023: 100: e1095-e1108. Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study - PMC
37. Redenbaugh et al. Ann. Neurol. 2024: 96: 34-45. Diagnostic Utility of MOG Antibody Testing in Cerebrospinal Fluid - Redenbaugh - 2024 - Annals of Neurology - Wiley Online Library

38. Greco et al. J Neurol Neurosurg Psychiatry. 2024: 333554. Clinical, prognostic and pathophysiological implications of MOG-IgG detection in the CSF: the importance of intrathecal MOG-IgG synthesis | Journal of Neurology, Neurosurgery & Psychiatry
39. Sechi et al. Mult Scler. 2021; 27: 303-308. Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies - PubMed
40. Jarius et al. J Neuroinflammation. 2016;13:230. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome - PubMed
41. Tonev and Momchilova. Biomedicines. 2023;11:328. Therapeutic Plasma Exchange in Certain Immune-Mediated Neurological Disorders: Focus on a Novel Nanomembrane-Based Technology - PubMed
42. American College of Rheumatology – Intravenous Immunoglobulin. Available from: Intravenous Immunoglobulin (IVIG) Accessed on September 30, 2024.
43. Spagni et al. J Neuro Neruosurg Psychiatry. 2023; 94:62-69. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis - PubMed
44. Hacohen et al. Jama Neruol. 2018; 75:478-487. Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease - PubMed
45. Sotirchos et al. Multi Scler Relat Disord. 2022;57:103462 Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin - PubMed
46. Bruijsten et al. Eur J Paediatr Neurol. 2020;29:41-53. E.U. paediatric MOG consortium consensus: Part 5 - Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders - PubMed
47. Chen et al. Mult Scler Relat Disord. 2022;68:104237. Details and outcomes of a large cohort of MOG-IgG associated optic neuritis - ScienceDirect
48. Kiessling. Sci Transl Med. 2017;9: 1208. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study - PubMed
49. Sechi et al. Front Neurol. 2022;13:885218. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management - PubMed
50. Yamamura et al. N Engl J Med. 2019;22:2114-22124. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder | New England Journal of Medicine
51. Sheppard et al. Hum Vaccin Immunother. 2017;13:1972-1988. Tocilizumab (Actemra) - PubMed
52. METEOROID-A clinical trial to compare satralizumab with placebo, with or without background therapy, in people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Available from:

https://forpatients.roche.com/en/trials/autoimmune-disorder/mog-antibody-disease/a-study-to-evaluate-the-efficacy--safety--pharmacokinet-94806.html Accessed on September 30, 2024.
53. TOMATO- Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease. Available from: https://clinicaltrials.gov/study/NCT06452537 Accessed on September 30, 2024.
54. Virupakshaiah et al. J Neurol Neurosurg Psychiatry. 2024;333464. Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease - PubMed
55. Liyanage et al. J Neurol Neurosurg Psychiatry. 2024 95: 544-553. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease - PubMed
56. Hyun et al. J Neurol Neurosurg Psychiatry. 2017: 88: 811-817 Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases | Journal of Neurology, Neurosurgery & Psychiatry
57. Whittam et al. J Neurol. 2020;267:3565-577. Treatment of MOG antibody associated disorders: results of an international survey - PubMed
58. Kwon et al. JAMA Neurol. 2024; 2811. Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease - PubMed
59. Levy et al. Mult Scler Relat Disord. 2023;72: 104613 Multiple types of relapses in MOG antibody disease - PubMed
60. Said et al. Mult Scler J Exp Transl Clin. 2024;10: 20552173241274605. Quality of life is impaired in myelin oligodendrocyte glycoprotein antibody associated disease - PubMed
61. MOGAD Clinic. Available from: MOGAD Clinic - Overview - Mayo Clinic Accessed on February 2 2025.
62. Rosenthal et al. JIM 2020:68: 321-330. CNS Inflammatory Demyelinating Disorders: MS, NMOSD and MOG Antibody Associated Disease - Jacqueline F Rosenthal, Benjamin M Hoffman, William R Tyor, 2020
63. Asseyer et al. Front Neurol. 2020: 11: 778. Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies - PubMed
64. Kubsik-Gidlewska et al. Adv Clin Exp med. 2017: 26: 709-715. Rehabilitation in multiple sclerosis - PubMed
65. MOG Antibody Disease Information. Available from: MOG Antibody Disease Information - MyMyelitis Accessed on February 2 2025.
66. Park et al. Brain Neurorehabil. 2021: 15:e9. Multidisciplinary Rehabilitation for Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease: A Case Report - PMC
67. Occupational Therapy in Neuro Rehab: Restoring Function and Independence. Available from: Occupational Therapy in Neuro Rehab: Restoring Independence Accessed February 2 2025.
68. De-Bernardi-Ojuel et al. Int J Environ Res Public health. 2021: 18:1432. Occupational Therapy Interventions in Adults with Multiple Sclerosis or Amyotrophic Lateral Sclerosis: A Scoping Review - PMC

69. Speech therapy: How it helps in multiple sclerosis. Available from: Speech therapy for multiple sclerosis (MS): An overview Accessed February 3 2025.
70. Tang. J Clin Exp Neuroimmunol. 2024: 9:4. Understanding Aphasia: A Speech Therapist's Approach to Neurological Disorders
71. Risi et al. J. Neurol. Sci. 2025: 470: 123413 Longitudinal assessment of cognitive function in patients with non-relapsing MOG-IgG associated disease - Journal of the Neurological Sciences
72. Unmet Needs and Challenges Across Pediatric and Adult MOGAD Populations. Available from: Unmet Needs and Challenges Across Pediatric and Adult MOGAD Populations. Accessed February 3 2025.
73. Understanding and Managing Multiple Sclerosis Mood Swings. Available from: Multiple Sclerosis Mood Swings Explained Accessed February 5 2025.
74. Neurobehavioral Therapy: Transforming Lives Through Brain-Based Interventions. Available from: Neurobehavioral Therapy: Brain-Based Interventions for Mental Health Accessed February 5 2025.
75. Turner and Knowles. Fed Pract. 2020: 37:S31-S35. Behavioral Interventions in Multiple Sclerosis - PMC
76. Optic Neuritis: How Long for recovery? Available from: Optic Neuritis: How Long for Recovery? – Eye Surgery Guide Accessed February 5 2025.
77. What is a Neuro-Ophthalmologist? Available from: What Are the Diseases Treated by Neuro-Ophthalmologists? Accessed February 5 2025.
78. Li et al. Neurology. 2020: 95: e2924-e2934. A clinico-neurophysiological study of urogenital dysfunction in MOG-antibody transverse myelitis - PubMed
79. DasGupta and Fowler. Therapy in Practice. 2003: 63: 153-166. Bladder, Bowel and Sexual Dysfunction in Multiple Sclerosis | Drugs
80. Bientinesi et al. Int neuronal J. 2020: 24: 118-126. Managing Urological Disorders in Multiple Sclerosis Patients: A Review of Available and Emerging Therapies - PMC
81. Pacing: an Essential Strategy for Living Better with Chronic Illness. Available from: Pacing: Mastering your energy to manage chronic illness better - Carenity Accessed February 5 2025.
82. Gupta et al. BMJ Open. 2023: 13:e060401. Sleep hygiene strategies for individuals with chronic pain: a scoping review - PMC \
83. Fatigue in the Context of MS. Available from: MS and Fatigue Fact Sheet | Cleveland Clinic Accessed February 6 2025.
84. Multiple Sclerosis (MS) and Sleep. Available from: MS and Sleep Disturbances: Insomnia, Nocturia, & Coping | Sleep Foundation. Accessed February 6 2025.